Literature DB >> 29620078

Acute polyneuropathy in a metastatic melanoma patient treated with vemurafenib and cobimetinib.

Annette Compter1, Willem Boogerd1, Johannes V van Thienen1, Dieta Brandsma1.   

Abstract

Entities:  

Year:  2017        PMID： 29620078      PMCID： PMC5874462          DOI： 10.1212/CPJ.0000000000000331

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN： 2163-0402


× No keyword cloud information.
  7 in total

Review 1.  Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data.

Authors:  James J Sejvar; Katrin S Kohl; Jane Gidudu; Anthony Amato; Nandini Bakshi; Roger Baxter; Dale R Burwen; David R Cornblath; Jan Cleerbout; Kathryn M Edwards; Ulrich Heininger; Richard Hughes; Najwa Khuri-Bulos; Rudolf Korinthenberg; Barbara J Law; Ursula Munro; Helena C Maltezou; Patricia Nell; James Oleske; Robert Sparks; Priscilla Velentgas; Patricia Vermeer; Max Wiznitzer
Journal:  Vaccine       Date:  2010-06-18       Impact factor: 3.641

2.  Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma.

Authors:  Oliver Klein; Antoni Ribas; Bartosz Chmielowski; Grant Walker; Arthur Clements; Georgina V Long; Richard F Kefford
Journal:  J Clin Oncol       Date:  2013-03-18       Impact factor: 44.544

3.  Gangliosides of human melanoma.

Authors:  T Tsuchida; R E Saxton; D L Morton; R F Irie
Journal:  Cancer       Date:  1989-03-15       Impact factor: 6.860

4.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors:  Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal:  N Engl J Med       Date:  2012-02-23       Impact factor: 91.245

5.  Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.

Authors:  Douglas B Johnson; Erika K Wallender; Daniel N Cohen; Sunaina S Likhari; Jeffrey P Zwerner; Jennifer G Powers; Lisa Shinn; Mark C Kelley; Richard W Joseph; Jeffrey A Sosman
Journal:  Cancer Immunol Res       Date:  2013-12       Impact factor: 11.151

6.  Vemurafenib-induced bilateral facial palsy.

Authors:  F N U Shailesh; M Singh; U Tiwari; L F Hutchins
Journal:  J Postgrad Med       Date:  2014 Apr-Jun       Impact factor: 1.476

7.  BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Authors:  Dennie T Frederick; Adriano Piris; Alexandria P Cogdill; Zachary A Cooper; Cecilia Lezcano; Cristina R Ferrone; Devarati Mitra; Andrea Boni; Lindsay P Newton; Chengwen Liu; Weiyi Peng; Ryan J Sullivan; Donald P Lawrence; F Stephen Hodi; Willem W Overwijk; Gregory Lizée; George F Murphy; Patrick Hwu; Keith T Flaherty; David E Fisher; Jennifer A Wargo
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531
  7 in total
  1 in total

Review 1.  Neurologic complications of immune checkpoint inhibitors.

Authors:  Alexandra M Haugh; John C Probasco; Douglas B Johnson
Journal:  Expert Opin Drug Saf       Date:  2020-03-11       Impact factor: 4.250
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.